Orexin/Hypocretin Type 2 Receptor (HCRTR2) Gene as a Candidate Gene in Sertraline-Associated Insomnia in Depressed Patients

Abstract

Background

Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line drugs for treating depressive disorders. Among the adverse effects reported with sertraline is sleep disturbances; however, the etiology lying beneath is obscure. Orexin, the most recently discovered neurotransmitter, is involved in the sleep cycle. It exerts its physiological actions through orexin or hypocretin type 1 and 2 receptors (HCRTR1 and HCRTR2). Dysfunction of the orexin system contributes to various psychiatric, neurologic and neuropsychiatric disorders. Thus, our study aimed to assess the possible association of genetic variation of HCRTR2 G1246A with hypersomnia reported with sertraline in a group of major depressive disorder (MDD) patients.

Patients and Methods

Ninety-six newly diagnosed MDD patients were enrolled in our cohort study. MDD was assessed using DSM-V criteria. Insomnia Severity Index (ISI) was used to assess insomnia at baseline (week 0) and week 4. Blood samples were collected for further genotyping of HCRTR2 G1246A (rs2653349) using polymerase chain reaction-restriction fragment length polymorphism.

Results

A significant association between G1264A polymorphism of HCRTR2 and insomnia was observed. Insomnia with sertraline happens by 2.5-fold (P=0.022; odds ratio (OR)=2.5; 95% confidence interval (CI): 1.1–5.7) in patients having GG genotype. Patients with G allele experience insomnia by 2.1-fold more than A allele carriers (P=0.022; OR=2.1; 95% CI= 1.1–4.0). Subgroup analysis showed a significant association between GG genotype as well as the G allele and insomnia only in female MDD patients (P=0.011; OR=4.0; 95% CI=1.3–12.0 and P=0.033; OR=2.4; 95% CI=1.02–5.7, respectively).

Conclusion

In conclusion, the G1246A variant might be a predictor for insomnia in MDD patients treated with sertraline. Our findings support the idea that some variants of the HCRTR might contribute to inter-individual variability in the sleep pattern of patients receiving antidepressants.

Keywords:

• orexin receptor 2
• sleep
• insomnia
• selective serotonin reuptake inhibitors
• sertraline

Introduction

Selective serotonin reuptake inhibitors (SSRIs) have emerged as first-line drugs for treating depressive disorders especially due to their minimal adverse effects and good tolerability.¹ However, despite their superior side effects profile over older antidepressants, they are still associated with various adverse drug reactions. Among these side effects, sleep disturbances have been frequently reported with SSRIs. Comparing two of the most widely used SSRIs, fluoxetine and sertraline, sertraline-treated patients exhibit a greater frequency of somnolence.² Sleep disturbances among patients treated with sertraline were as follows: 35.6% insomnia, 26.5% hypersomnia, 39.3% mixed insomnia-hypersomnia and 18.8% no sleep disturbance.³

Many neurotransmitters in the brain such as ɣ-aminobutyric acid (GABA), serotonin and norepinephrine are responsible for sleep control. Orexin/hypocretin has been found in the hypothalamus areas rich in sleep-active neurons.⁴ This discovery adds to the list of neurotransmitters involved in the sleep cycle. It has been proposed that orexin and its receptors have a substantial role in conducting the sleep/wakefulness cycle.^5–11 An important issue is the projection of orexin neurons to norepinephrine and serotonin neurons responsible for arousal.^12,13 Serotonergic neurons located in the nucleus dorsalis raphe play a pivotal role in many physiological processes including sleep/arousal and mood control.¹⁴ Orexin stimulates serotonergic neurons in the dorsal raphe nucleus.¹³ Two types of orexin receptors, orexin/hypocretin type 1 receptor (HCRTR1) and orexin/hypocretin type 2 receptor (HCRTR2) were also found to be lavishly expressed in these monoaminergic nuclei.^15,16 Dysfunction of the orexin system contributes to various psychiatric, neurologic and neuropsychiatric disorders.⁹ Changes in serum the levels of orexin are related to neuronal activity and sleep cycle.^17,18 Orexin levels display a diurnal pattern in which, orexinergic neurons are activated during wakefulness and being practically silent during normal sleep.^18–20 Although not yet fully understood, aberrant activation of the orexin neurons during the night might contribute to insomnia.²¹ Orexin receptor agonists would be of potential value for treating narcolepsy and conditions of excessive daytime sleepiness in humans. Likewise, dual orexin receptor antagonists, have potential as new medications for the treatment of insomnia.²²

Orexin receptors (HCRTR1 and HCRTR2) are the G-protein coupled receptors with a seven-membrane domain. Generally, HCRTR1 is coupled to Gq, and HCRTR2 signals through Gq or Gi/Go. However, the coupling mechanisms appear to be different in various cell types and it is not thoroughly studied in neurons.^23,24 Although the genetic deletion of HCRTR1 in mice shows no impact on sleep/wakefulness pattern, disruption of HCRTR2 causes modest sleepiness.²⁵

Among the many factors affecting drug response and adverse drug reactions, genetics is presumed to be an accountable parameter.²⁶ Reports have studied HCRTR2 polymorphisms.^27–37 G1246A (rs2653349) on HCRTR2 causes an amino acid replacement of valine with isoleucine at position 308, which could alter receptor function. Thus we performed an association study in a cohort of MDD patients treated with sertraline to evaluate whether a certain genotype or allele of HCRTR2 (G1246A) would influence the occurrence of insomnia in this group of MDD patients.

Patients and Methods

Patients

The study was approved by the Ethics committee of Shiraz University of Medical Sciences and was following the Declaration of Helsinki. Written patient informed consent was obtained from each individual. A group of 96 unrelated, newly diagnosed MDD patients, 57 females and 39 males with a mean age of 38.3±12.6 years (mean age ± SD), recruited from Hafez Hospital, Shiraz University of Medical Sciences, were selected for the study and followed during 4 weeks by an experienced psychiatrist. The diagnosis of MDD was based on DSM-5 criteria.³⁸ Patients had no previous history of sleep disturbances during the last 6 months. Newly diagnosed was defined as no previous history of MDD and no concomitant antidepressant use. Patients with either of the following conditions were excluded from our study. Family history and/or personal history of schizophrenia, family history and/or personal history of bipolar disorder, anxiety disorders, manic or hypomanic episode, mood incongruent psychotic symptoms, and active substance dependence, no cigarette smoking, no history of alcohol abuse or dependence and current treatment with antipsychotics or mood stabilizers. No history of conditions that may predispose to depression or sleepiness/insomnia/hypersomnia such as hypothyroidism, etc. Patients were asked not to use any alcohol and caffeine-containing beverages/food during the study. None of the patients experienced any sleep disturbances at baseline (week 0).

Insomnia Severity Index (ISI)

At the time of MDD diagnosis (week 0) and after 4 weeks of sertraline use, the ISI was calculated for each patient. ISI is a reliable and valid instrument for evaluation and quantification of insomnia severity and is a clinically suitable tool for measuring treatment-related insomnia outcomes.³⁹

Drug Administration

Sertraline (SERTRALINE-ABIDI^®, Abidi factory Tehran, Iran) was administered at a fixed-dose regimen of 50 mg for one week initially as previously described.⁴⁰ The dose could be increased by 50 mg/day per week to a maximum of 200 mg/day according to clinical response over the 4 weeks of treatment duration.

Evaluation of insomnia was done at baseline, weeks 0 and 4 of treatment. Before interviewing and after obtaining the informed written consent, 5mL of venous blood samples were collected for further genotyping.

Genotyping

A blood sample was taken at baseline (week 0) for further genotyping assays. DNA extraction was carried out using a standard protocol.⁴¹ Genotyping of HCRTR2 (G1246A) was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method (Table 1) and in a final volume of 25 µL and as described by Pinessi et al.²⁸ PCR products were digested with Mbo I restriction enzyme (Thermo Fisher Scientific, Waltham, Massachusetts). Electrophoresis on 2.5% agarose (Invitrogen^® Ultra Pure, Waltham, Massachusetts) gel was used to separate digested fragments. They were then stained by ethidium bromide and visualized in a UV transilluminator. All samples were genotyped at least twice and reconfirmed.

Table 1 Primer Sequences and G1246A Polymorphism Properties

Polymorphism	Primer Sequence (5ʹ–3ʹ)	Restriction Enzyme	Genotypes	DNA Fragment Size (bp)
G1246A (rs2653349)	5- CCTTTCAGATCCCTGGAACA −3 (sense) 5- CAAATTGCAAATACCAAAAGCA −3 (anti-sense)	MboI	GG GA AA	120, 60 120, 60, 40 120,40

Statistical Analysis

Data analysis was performed using SPSS^® 21.0 for windows^® (SPSS Inc., Chicago, Illinois). Continuous variables are demonstrated as mean ± S.D. Genotype frequencies are presented in percentage (%). Hardy–Weinberg equilibrium (HWE) for the distribution of genotypes was calculated. Kolmogorov–Smirnov test was used to test the normal distribution of continuous variables. Associations between categorical variables were calculated by Pearson’s chi-square or Fisher’s exact test and for interval data by Student’s t-test. χ2 test was performed for univariate analysis of genotypes. Odds ratio (OR) and 95% confidence intervals (CI) were calculated. P-value <0.05 was considered as statistically significant.

Results

Demographic data are presented in Table 2. As it is demonstrated no significant difference was observed regarding sex and age between groups with insomnia and No insomnia group (P=0.658 and 0.321 respectively). As shown in Table 3, estimating ISI scores reveals a significant change between week 0 and week 4 in the insomnia group (P=0.001). Table 4 demonstrates genetic variations in two groups of patients receiving sertraline, one group experiencing insomnia after a 4-week course of sertraline treatment and the other one not experiencing insomnia. As shown in Table 4, our study indicates a significant association between G1264A polymorphism (rs2653349) of HCRTR2 and insomnia with sertraline. Insomnia happens by 2.5-fold (P=0.022; OR=2.5; 95% CI: 1.1–5.7) in patients with GG genotype. Patients with the G allele experience insomnia 2.1 fold more than carriers of the A allele (P=0.022; OR=2.1, 95% CI= 1.06–4.0). As shown in Table 5, subgroup analysis showed a significant association between GG genotype as well as the G allele and insomnia only in female MDD patients (P=0.011; OR=4.0, 95% CI=1.3–12.0 and P=0.033; OR=2.4, 95% CI=1.02–5.7 respectively).

Table 2 Clinical and Demographic Characteristics of the Study Samples

Variable	No Insomnia (N=46)	Insomnia (N=50)	P-value
Sex (male/female)	19/27	20/30	0.531
Age (years) mean±SD	40.5±12.6	40.2±12.7	0.907

Table 3 ISI Scores of Enrolled Patients at Baseline (Week 0) and Week 4 of Treatment with Sertraline

	ISI Week 0	ISI Week 4	P-value
Sertraline-induced Insomnia (N=50)	5.06±1.99	16.96±2.12	0.0001
No insomnia (N=46)	6.80±1.77	6.20±1.69	0.0998

Notes: ISI (Insomnia Severity Index) scores in week 0 and week 4 of treatment with sertraline.

Table 4 Genotype and Allele Distribution of G1246A Variant in Study Groups

Polymorphism	Variant	No Insomnia (N=46)	Insomnia (N=50)	Pc	OR	95% CI
rs2653349				0.022	2.5	1.1–5.7
	GG	19 (41.3%)	32 (64.0%)
	GA	24 (52.2%)	17 (34.0%)
	AA	3 (6.5%)	1 (2.0%)
Alleles				0.022	2.1	1.1–4.0
	G	62 (67.4%)	81 (81.0%)
	A	30 (32.6%)	19 (19.0%)

Abbreviations: Pc, P-value for χ² test; OR, odds ratio; CI, confidence interval.

Table 5 Genotype and Allele Distribution of G1246A Variant in Female and Male Patients

Polymorphism	Variant	No Insomnia	Insomnia	Pc	OR	95% CI
rs2653349 Female (N=57)				0.011	4.0	1.3–12.0
	GG	9 (33.3%)	20 (66.7%)
	GA	17 (63.0%)	9 (30.0%)
	AA	1 (3.7%)	1 (3.3%)
Alleles				0.033	2.4	1.02–5.7
	G	35 (64.8%)	49 (81.7%)
	A	19 (35.2%)	11 (18.3%)
rs2653349 Male (N=39)				0.444	1.3	0.4–4.8
	GG	10 (52.6%)	12 (60.0%)
	GA	7 (36.9%)	8 (40.0%)
	AA	2 (10.5%)	0 (0.0%)
Alleles				0.25	1.6	0.6–4.6
	G	27 (71.1%)	32 (80.0%)
	A	11 (28.9%)	8 (20.0%)

Abbreviations: Pc, P-value for χ² test; OR, odds ratio; CI, confidence interval.

Discussion

The results of our study indicate a significant association between G1264A polymorphism of HCRTR2 (rs2653349) and insomnia. Insomnia with sertraline happens by 2.5-fold in patients having the GG genotype. Patients with the G allele experience insomnia 2.1-fold more than carriers of the A allele. Subgroup analysis showed a significant association between GG genotype as well as the G allele and insomnia only in female MDD patients (P=0.011; OR=4.0, 95% CI=1.3–12.0 and P=0.033; OR=2.4, 95% CI=1.02–5.7 respectively).

Our data suggest that the orexin system may be involved in the process of sleep and arousal in MDD patients treated with sertraline. Orexins have been shown to influence a wide range of physiologic and behavioral processes. Aberrant activation of the orexin neurons at night might contribute to signs of insomnia such as increased natural metabolic rate.⁴² The orexin peptides apply their most prominent behavioral effects on sleep and awakening through HCRTR2 particularly.²¹ Suvorexant and almorexant, two orexin receptor antagonists, have been shown to stimulate sleep in both animals and men.^22,43,44 In general, orexins depolarize neurons and induce neural excitability and firing. Several ionic channels are involved in their signaling mechanisms. Rise in intracellular calcium through voltage-gated calcium channels and activation of sodium/calcium exchanger contribute to the excitatory mechanism of orexins and their role in arousal.^45,46 Although not much is known about the exact role of HCRTRs in sleep and arousal, several genetic studies have revealed their part in this matter. For example, functional mutations in the HCRTR2 gene were found in dogs and mice with familial narcolepsy.^5,25 Orexin B failed to depolarize orexin neurons in the HCRTR2 knock-out mice. Immunoelectron microscopic observations have shown tight contacts among orexin neurons which unveiled structural resemblances to the glutamatergic synapses.⁴⁷ All these reports suggest that HCRTR2 is a primary receptor in sleep and arousal. Though this causal link between narcolepsy/hypersomnia and loss of orexin signaling sometimes through alteration in HCRTR2 brought about the possibility that some mutations on HCRTR2 might contribute to this matter.

Polymorphism of G1246A (rs2653349) on HCRTR2 has been previously reported to be associated with different neurologic and psychiatric disorders.^27,29,32,48 The 1246G→A polymorphism (rs2653349) of the HCRTR2 gene makes an amino acid substitution of valine to isoleucine at position 308, which could cause alteration in receptor function. Different studies reveal a decline of orexin neurons and HCRTR2 in narcolepsy and depression respectively.⁹ The result of our study shows that carriers of the G allele confront insomnia 2.1 times more than carriers of the A allele. Since binding of orexins to HCRTR2 stimulates calcium influx into the neurons and causes post-synaptic excitatory effects^49,50 it may be postulated that mutation in the HCRTR2 gene might cause changes in HCRTR2 binding sites and interrupt calcium influx. As a consequence, the HCRTR2 will be less stimulated and arousal is perturbed. So based on our results it is presumed that patients with the wild allele and genotype do not encounter perturbation in arousal but experience insomnia. The latest studies suggest that G-protein coupled receptors such as HCRTR2 may form dimers as part of their regular cellular trafficking and function.^51,52 Substitution of valine –isoleucine might be at the dimer interface and influence the dimerization process of the receptor,³⁰ hence affecting the signaling process of HCRTR2 and as a consequence influence the sleep-wake process.

Dividing our study population to men and women revealed a significant association between GG genotype as well as the G allele with insomnia in women treated with sertraline and not men. Since G1246A polymorphism (rs2653349) is located on HCRTR2 within the chromosome 6p12 and not the sex chromosomes, it could be postulated that this finding might be due to higher frequency of enrolled female patients (57female/39male). It is worth mentioning that women are approximately twice as likely as are men to develop depression during their lifetime.⁵³ So it was logical that enrollment of MDD patients leads to a higher frequency in women rather than men. Additionally, it is worth mentioning that the regulation of the orexin/hypocretin system is sexually dimorphic and that sexual hormones modulate this system and affect HCRTRs expression. On the other hand, orexins participate in the regulation of the hypothalamic-pituitary-gonadal axis.^54,55 A previous study indicates that the administration of an HCRTR2 antagonist, JNJ-10397049, resulted in decreased serum levels of gonadotropins and ova numbers in female rats.⁵⁶ Another study in postmortem human brain reported that hypothalamic orexin/hypocretin is increased in depressed women and not depressed men and HCRTR2⁵⁷ mRNA expression was elevated in depressed men who committed suicide and not in depressed women.⁵⁸ However, how the variants of rs2653349 affect the levels of gonadal hormones as well as how sex hormones affect expression of orexin receptors in carriers of different genotypes of G1246A is still unclear.

As a limitation of our study, it must be addressed that measuring serum levels of sertraline at the baseline and after the course of treatment would have provided many vivid results. Moreover, sertraline is mainly metabolized by CYP2C19. Individuals carrying one or two alleles encoding defective CYP2C19 metabolism show significantly higher serum levels of sertraline.⁵⁹ This parameter, as well as other genetic parameters, may influence serum levels of sertraline and thus affect both clinical response and extent of side effects such as insomnia. It can be speculated that patients with the GG genotype of G1246A might also have the allele of CYP2C19 which causes higher serum levels of sertraline and as a result, higher chance of insomnia. However, this hypothesis should be further studied. Therefore, it is suggested to measure serum levels of sertraline in patients with different genotypes of G1246A on HCRTR2 to assess the relationship between these variants, sertraline serum level and prevalence of insomnia.

In summary, we provide preliminary data that genetic variation in the HCRTR2 gene is associated with insomnia in MDD patients taking sertraline. Analysis of this gene in larger sample sets will provide a much subtle picture of the contribution of this variant in insomnia associated with sertraline.

Author Contributions

Negar Firouzabadi was responsible for study design, providing the funding for this study, statistical analysis, and manuscript preparation. Niloofar Navabzadeh was responsible for recruiting the subjects, methodology, performing the clinical rating, collecting the samples and editing the manuscript. Ebrahim Moghimi Sarani was responsible for collecting the samples, drafting or revising the article and gave the final approval of the version to be published. Maral Haghnegahdar was responsible for methodology, drafting or revising the article and gave the final approval of the version to be published. Negar Firouzabadi wrote the paper. All authors have contributed to and have approved the final manuscript. All authors declare that they have no conflicts of interest. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Acknowledgments

This work was financially supported by a grant from the Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran (Grant No. 1396-01-05-14116). The project was a part of a Pharm.D, thesis by Niloofar Navabzadeh, Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

Disclosure

The authors declare that they have no known competing interests or personal relationships that could have appeared to influence the work reported in this paper.